PMID- 25684180
OWN - NLM
STAT- MEDLINE
DCOM- 20160822
LR  - 20220310
IS  - 1752-8062 (Electronic)
IS  - 1752-8054 (Print)
IS  - 1752-8054 (Linking)
VI  - 8
IP  - 4
DP  - 2015 Aug
TI  - Clinicopathologic Implications of Eukaryotic Initiation Factor 3f and Her-2/neu 
      Expression in Gastric Cancer.
PG  - 320-5
LID - 10.1111/cts.12263 [doi]
AB  - BACKGROUND: To detect the expression of eIF3f and human epidermal growth factor 
      receptor 2 (Her-2)/neu in gastric cancer (GC), correlation with their 
      clinicopathological parameters and the relationship of eIF3f and Her-2/neu in the 
      occurrence and development of GC. METHODS: A total of 195 gastrectomy specimens 
      with stage I to III were examined for eIF3f expression by immunohistochemistry 
      and for Her-2/neu expression by fluorescence in situ hybridization (FISH) with 
      the median follow-up period of 38 months. RESULTS: The positive expression rate 
      of eIF3f in GC and adjacent noncancerous tissue were 33.8% and 59.5%, 
      respectively. eIF3f levels were linked to more advanced tumor stages and 
      likelihood of recurrence (all p < 0.05). The Kaplan-Meier survival curves 
      indicated that decreased expression of eIF3f could serve as a prognosis marker 
      for poor outcome of GC patients (p = 0.04). 15.9% of GC specimens were positive 
      for Her-2/neu, but whose expression was of no correlation with patients' 
      survival. Patients who were positive for Her-2/neu also had high eIF3f expression 
      levels (p = 0.0295). CONCLUSION: Results suggest that eIF3f may play an important 
      role in recurrence, thus representing a promising predictive marker for the 
      prognosis of GC. But Her-2/neu has no relationship with the prognosis of GC. The 
      clinical significance of eIF3f and Her-2/neu remains to be further investigated.
CI  - (c) 2015 Wiley Periodicals, Inc.
FAU - Cheng, Yu
AU  - Cheng Y
AD  - Department of First Medical Oncology, Affiliated Yantai Yuhuangding Hospital of 
      Qingdao University Medical, Yantai, Shandong, China.
FAU - Zhou, Jin
AU  - Zhou J
AD  - Department of Endocrinology, Affiliated Yantai Yuhuangding Hospital of Qingdao 
      University Medical, Yantai, Shandong, China.
FAU - Li, Honglun
AU  - Li H
AD  - Department of Radiology, Affiliated Yantai Yuhuangding Hospital of Qingdao 
      University Medical, Yantai, Shandong, China.
LA  - eng
PT  - Journal Article
DEP - 20150214
PL  - United States
TA  - Clin Transl Sci
JT  - Clinical and translational science
JID - 101474067
RN  - 0 (EIF3F protein, human)
RN  - 0 (Eukaryotic Initiation Factor-3)
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Eukaryotic Initiation Factor-3/*analysis
MH  - Female
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Prognosis
MH  - Receptor, ErbB-2/*analysis
MH  - Stomach Neoplasms/chemistry/mortality/*pathology
PMC - PMC5351038
OTO - NOTNLM
OT  - Her-2/neu
OT  - biomarker
OT  - eIF3f
OT  - gastric cancer
OT  - prognosis
EDAT- 2015/02/17 06:00
MHDA- 2016/08/23 06:00
PMCR- 2015/08/01
CRDT- 2015/02/17 06:00
PHST- 2015/02/17 06:00 [entrez]
PHST- 2015/02/17 06:00 [pubmed]
PHST- 2016/08/23 06:00 [medline]
PHST- 2015/08/01 00:00 [pmc-release]
AID - CTS12263 [pii]
AID - 10.1111/cts.12263 [doi]
PST - ppublish
SO  - Clin Transl Sci. 2015 Aug;8(4):320-5. doi: 10.1111/cts.12263. Epub 2015 Feb 14.